CA
NZ
UK
AU
IND
US
Analysts retain ‘Buy’ rating on Phreesia as the software solutions provider reported its results for Q1’24. Refinitiv data suggests an overall ‘Strong Buy’ rating as on the stock. Phreesia reported a total revenue of US$ 83.8 million for the three months
Wells Fargo upgraded its rating on PVH Corp. (NYSE: PVH) to ‘Overweight’ post the release of the company’s Q1 2023 results. The company reported first quarter revenue of US$ 2.158 billion, higher than the company expectations of no major change over the p
Brokers maintain ‘Buy’ rating on Capital Southwest Corp. (NASDAQ: CSWC) post the release of the company’s financial results in Q4 FY23. The consensus mean price target on the stock was US$ 21.56 as on May 31, 2023.
Brokers upgraded AutoZone Inc. (NYSE: AZO) to ‘Buy’. The consensus mean price target on the stock was US$ 2,764.29 as on May 30, 2023.
Brokers upgraded on AutoZone Inc. (NYSE: AZO) to ‘Buy’ rating. The consensus mean price target on the stock is US$ 2,764.29 as on May 30, 2023.
Brokers have retained ‘Buy’ rating on Onconova Therapeutics (NASDAQ: ONTX). The mean price target on the stock is US$ 7.5. Onconova announced commencement of its drug trial.
Brokers have retained ‘Buy’ rating on Onconova Therapeutics (NASDAQ: ONTX). The mean price target on the stock is US$ 7.5. Onconova announced commencement of its drug trial.
Brokers have revised their ratings on Fabrinet (NYSE: FN) post the announcement of its results for Q3 FY23. The consensus price target on the stock was US$ 122, which is 24.06% higher than its closing price of US$ 93.8 on May 23, 2023.
Brokers have retained their ‘Buy’ rating on Disc Medicine (NASDAQ: IRON). The consensus price target on the stock was US$ 40.75, which is 20.56% higher than its closing price of US$ 33.8 on May 19, 2023.
Brokers have given ‘Buy’ rating on Perion (NASDAQ: PERI). The consensus price target on the stock was US$ 38.81 as on Monday, May 16, 2023, according to data available on Refinitiv.
Please wait processing your request...